MNPR rises as buyers remain active during intraday volatility
Monopar Therapeutics (MNPR) stock is trading at $82.09, up 4.64% for the day. The price is currently positioned above its key short- and long-term moving averages.
73.6700
75.2600
Highlights
- MNPR/USD trades with a bullish technical structure, staying above all key moving averages on the hourly chart.
- Momentum indicators mostly signal bearish or neutral momentum, with only intraday buyer dominance and volatility suggesting recent upside.
- Forecast range for the next 2 to 3 days is $79.50 to $84.68, with 63% probability of a downward move and likely consolidation.
Technical divergence as support holds and momentum signals weaken
On the H1 timeframe, MNPR is trading above the MA-20 at $78.27, MA-50 at $81.10, and the longer-term MA-200 at $76.49. The Ichimoku Kijun is positioned at $79.23, marking immediate support. Momentum readings show MACD on Strong Sell and ADX indicating Sell, while RSI at 44.47 is in Sell territory. CCI and Stoch RSI are Neutral, Bull/Bear Power signals active buyer dominance intraday, and the Awesome Oscillator is Neutral. A small negative gap was observed from the previous close, alongside high intraday volatility.
Sideways bias as downside risk outweighs breakout potential
The short-term forecast expects MNPR to consolidate within a $79.50 to $84.68 band over the next 2–3 trading days, reflecting the current volatility range. There is a 37% probability of an upward move, while a downward move is more likely at 63%. The baseline expectation is sideways consolidation; a break above $84.68 would signal renewed buying strength, while a drop below $79.50 would set the stage for further weakness.
Earlier, analysts noted that Monopar Therapeutics was facing ongoing selling pressure, with downside risk prevailing amid heightened volatility. The latest technical setup shows the stock recovering above key moving averages but with mixed momentum indicators, making the $84.68 resistance level crucial for traders watching for a potential breakout in the near term.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
